Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Rab coupling protein (FIP1C), an effector of Rab11 GTPases, is overexpressed in 10-25% of breast cancers, correlating with poor outcomes.
• Rab25's dual role as an oncogene or tumor suppressor, depending on breast cancer subtype, highlights the need to understand FIP family member roles.
• The specific pathobiological function of FIP1C in tumor development remains largely unknown.

Purpose of the Study:

• To investigate the role of FIP1C in tumorigenesis using ErbB2 mouse models of human breast cancer.
• To elucidate the molecular mechanisms by which FIP1C influences tumor progression and ErbB2 signaling.

Main Methods:

• Utilized MMTV-ErbB2 mouse models with doxycycline-induced FIP1C expression and targeted FIP1C deletion.
• Conducted genetic and biochemical analyses to characterize FIP1C-proficient and -deficient tumors.
• Assessed the impact of FIP1C on E-cadherin trafficking, ZONAB function, Cdk4-mediated cell-cycle progression, and ErbB2 lysosomal degradation.

Main Results:

• Induced FIP1C expression delayed mammary tumor progression, while FIP1C deletion accelerated tumor onset in ErbB2 models.
• FIP1C was found to regulate E-cadherin (CDH1) trafficking and ZONAB (YBX3) function in cell-cycle progression.
• FIP1C promoted the lysosomal degradation of ErbB2, and its expression inversely correlated with ErbB2 levels in human breast cancer patients.

Conclusions:

• FIP1C functions as a tumor suppressor in ErbB2-positive breast cancer.
• FIP1C influences key pathways including E-cadherin trafficking, cell-cycle control, and ErbB2 degradation.
• FIP1C represents a potential therapeutic target for managing aberrant ErbB2 expression in breast cancer.